Sonia Guedan

TL;DR: The influence of signaling domains of coreceptors CD28 and 4-1BB on the metabolic characteristics of human CAR T cells is reported to provide a mechanistic insight into the differential persistence of CAR-T cells expressing 4- 1BB or CD28 signaling domains in clinical trials and inform the design of future CAR T cell therapies.

TL;DR: CARs with ICOS and 4-1BB ICD demonstrate increased efficacy in solid tumor models over the current 4- 1BB-based CAR and are promising therapeutics for clinical testing.

TL;DR: It is demonstrated that redirection of primary human T cells with a CAR containing the inducible costimulator (ICOS) intracellular domain generates tumor-specific IL-17-producing effector cells that show enhanced persistence.

TL;DR: It is reported that certain CARs endow T cells with the ability to undergo long-term autonomous proliferation and the design of CARs that have a nonconstitutive growth phenotype may be a strategy to improve efficacy and engraftment of CAR T cells.

TL;DR: Advances in T cell engineering, genetic editing, the selection of optimal lymphocytes, and cell manufacturing have the potential to broaden T cell-based therapies and foster new applications beyond oncology, in infectious diseases, organ transplantation, and autoimmunity.